Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.
Real-world characterization of advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) with rapid disease progression (RDP).
Metastatic Non-Small Cell Lung Cancer
Lung Cancer—Non-Small Cell Metastatic
2019 ASCO Annual Meeting
J Clin Oncol 37, 2019 (suppl; abstr e20706)
Author(s): Martin Gutierrez, Cliff Molife, Andrew J. Belli, Eric Hansen, Victoria Jennifer Stefaniak, Katherine B. Winfree, Zhanglin Lin Cui, Marta Batus, Jeffrey Melson Clarke, Viraj Narayanan, Chelsea Manion, Andrew David Norden, Philip D. Bonomi; Hackensack University Medical Center, Hackensack, NJ; Eli Lilly and Company, Indianapolis, IN; COTA, Inc., New York, NY; Rush University Medical Center, Chicago, IL; Duke University Medical Center, Durham, NC
Background: Despite advances in therapy, recent observational data shows that aNSCLC pts with RDP continue to have a poor prognosis. This retrospective, observational study characterizes the demographic, molecular, & treatment profile of pts with RDP. Methods: Adult aNSCLC pts receiving first-line (1L) platinum-based (Pt) therapy between 01/2014 - 12/2018 were identified in the COTA Real-World Evidence database and assigned to RDP (n = 280) & non-RDP (n = 1,212) cohorts based on time to progression during 1L Pt therapy (≤ 12 and > 12 weeks, respectively). Results: Of 1,492 eligible pts, the incidence of RDP was 19%. Mean age (±SD) was 64.6 (10.9) and 66.1 (10.2) in the RDP and non-RDP group, respectively (p = 0.04). Data showed RDP patients had higher percentage of stage IV disease at diagnosis (77 v 72, p < 0.01), higher histologic grade G3/G4 (37 v 29, p = 0.01), and PD-L1 negative (< 1% expression) status (p = 0.01). Table shows molecular profiling across cohorts. No notable difference in treatment patterns across 1L and 2L was observed. Conclusions: This study identifies stage IV disease at diagnosis, higher grade, & PD-L1 negative ( < 1% expression) as potential risk factors for RDP. A better understanding of this poor prognosis cohort may offer an opportunity to better optimize therapies & outcomes.
|Molecular Profiling, positive/tested, %||All|
N = 1,492
N = 280
N = 1,212
|Positive, qualitative determination||9||10||9||0.01|
|Positive, 1% - 49%||36||24||38|
|Tumor Mutational Burden|